Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma

Abstract Background Glioblastoma (GBM) is one of the most aggressive and vascularized brain tumors in adults, with a median survival of 20.9 months. In newly diagnosed and recurrent GBM, bevacizumab demonstrated an increase in progression-free survival, but not in overall survival. Methods We conduc...

詳細記述

保存先:
書誌詳細
主要な著者: N. García-Romero, I. Palacín-Aliana, R. Madurga, J. Carrión-Navarro, S. Esteban-Rubio, B. Jiménez, A. Collazo, F. Pérez-Rodríguez, A. Ortiz de Mendivil, C. Fernández-Carballal, S. García-Duque, J. Diamantopoulos-Fernández, C. Belda-Iniesta, R. Prat-Acín, P. Sánchez-Gómez, E. Calvo, A. Ayuso-Sacido
フォーマット: Artigo
言語:Inglês
出版事項: BMC 2020-06-01
シリーズ:BMC Medicine
主題:
VEGFA
Angiogenesis
Bevacizumab
Glioblastoma
Neovasculogenesis
オンライン･アクセス:http://link.springer.com/article/10.1186/s12916-020-01610-0
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料